Treatment strategies for breast cancer subtypes are determined by the tumor expression status of estrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor receptor 2 (HER2) [3–5]. This evidence concerns the gene ERBB2 and breast carcinoma.